^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
LM-061
i
Other names: LM-061, LM061, LM 061
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
LaNova Medicines Limited
Drug class:
Kinase inhibitor
Related drugs:
1year
Study of LM-061 in Subjects in Advanced Tumors (clinicaltrials.gov)
P1, N=18, Terminated, LaNova Medicines Limited | N=37 --> 18 | Recruiting --> Terminated; Failure to achieve expected outcomes
Enrollment change • Trial termination • Metastases
|
Loqtorzi (toripalimab-tpzi) • LM-061
over1year
A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours (clinicaltrials.gov)
P1/2, N=18, Terminated, LaNova Medicines Limited | N=87 --> 18 | Trial completion date: Aug 2024 --> Jul 2023 | Recruiting --> Terminated | Trial primary completion date: Jul 2023 --> Feb 2023; Not meeting expected endpoints
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET amplification • MET exon 14 mutation • MET mutation • MET expression
|
LM-061
over3years
A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours (clinicaltrials.gov)
P1/2, N=87, Recruiting, LaNova Medicines Limited | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET amplification • MET exon 14 mutation • MET mutation • MET expression
|
LM-061
over3years
A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours (clinicaltrials.gov)
P1/2, N=87, Not yet recruiting, LaNova Medicines Limited
Clinical • New P1/2 trial
|
EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET amplification • MET exon 14 mutation • MET mutation • MET expression
|
LM-061
Share via
